By targeting both EGFR-mediated survival pathways and the mitotic checkpoint, this combination therapy aims to enhance the overall anti-cancer effect, leading to increased cancer cell death and improved treatment outcomes in oral cancer. This evidence concerns the gene EGFR and cancer.